Corcept Therapeutics Incorporated (CORT) Stock Analysis & AI Equity Report
Corcept Therapeutics Incorporated (CORT) overview
Corcept Therapeutics Incorporated (CORT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 761m and operating profit of USD 44.8m; the year-end share price was 34.80 USD and market capitalisation was USD 3,688m. Corcept Therapeutics Incorporated is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Corcept Therapeutics Incorporated's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Corcept Therapeutics Incorporated
Corcept Therapeutics discovers, develops, and commercializes medicines that modulate cortisol for endocrinologic, oncologic, metabolic, and neurologic disorders. Its marketed products include Korlym and an authorized generic for hypercortisolism, as well as Lifyorli (relacorilant) for use with chemotherapy in platinum-resistant ovarian cancer. The company is also developing relacorilant for Cushing’s syndrome and other cortisol modulators for additional conditions.
Generate the Corcept Therapeutics Incorporated report
Corcept Therapeutics Incorporated is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Corcept Therapeutics Incorporated and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Corcept Therapeutics Incorporated
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.